Allogeneic Stem Cell Transplantation Compared with Chemotherapy for Poor-Risk Hodgkin Lymphoma

Luca Castagna, Barbara Sarina, Elisabetta Todisco, Massimo Magagnoli, Monica Balzarotti, Stefania Bramanti, Rita Mazza, Antonella Anastasia, Andrea Bacigalupo, Franco Aversa, Davide Soligo, Laura Giordano, Armando Santoro

Research output: Contribution to journalArticlepeer-review


The aim of this study was to assess the role of allogeneic hematopoietic stem cell transplantation (HSCT) in patients with poor-risk Hodgkin's disease (HD) compared to chemotherapy. A donor was identified in 26 patients (14 HLA identical siblings and 10 alternative donors), and 24 received a transplant (Allo group). Twenty patients without a donor received different chemotherapy regimens and radiotherapy (CHEMO group). After a median follow-up of 28 months (range: 1-110), the 2-year overall survival (OS) was 71% in the ALLO group compared to 50% in the CHEMO group (P = .031). In the Allo group, the 2-year progression-free survival (PFS) was 47%. The 1-year nonrelapse mortality (NRM) in the ALLO group was 8% versus 0% in the CHEMO group. This study, suggests that allogeneic transplantation may prolong the survival in patients with a poor-risk HD.

Original languageEnglish
Pages (from-to)432-438
Number of pages7
JournalBiology of Blood and Marrow Transplantation
Issue number4
Publication statusPublished - Apr 2009


  • Allogeneic transplantation
  • High-dose chemotherapy
  • Hodgkin lymphoma
  • Salvage chemotherapy

ASJC Scopus subject areas

  • Transplantation
  • Hematology


Dive into the research topics of 'Allogeneic Stem Cell Transplantation Compared with Chemotherapy for Poor-Risk Hodgkin Lymphoma'. Together they form a unique fingerprint.

Cite this